DOCTIS has organized a symposium event focused on “Combination therapies in common diseases: clinical and translational challenges”. This event will be held on the 7th of October 2021, free of charge, online and will start at 5 p.m CET, sponsored by IMIDomics.
DOCTIS is the acronym for the EU-funded project entitled “Decision on Combinatorial Therapies in Immune-Mediated diseases using Systems approaches” aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs), encompassing: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and psoriatic arthritis.
Despite major advances in the molecular and cellular characterization of common diseases, there has been a steady decline of new effective therapies. Also within approved drugs, significant clinical efficacy is only observed in a subset of patients. Combination therapies could be a useful strategy to overcome this major medical problem. This virtual symposium will be a venue to share insights on the clinical and translational challenges of discovering and implementing combination therapies in common diseases.
17:00 – 17:10: Welcome by Sara Marsal, coordinator of the DOCTIS project and Head of Rheumatology Department in Vall d’Hebron Hospital Campus, Barcelona, Spain.
The first block of presentations: Clinical Challenges. Moderated by Sara Marsal.
17:10 – 17:30: ‘Precision Medicine in Advanced Breast Cancer. – Cristina Saura, Head of Breast Cancer Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain
17:30 – 17:50: ‘Combination strategies in IBD: opportunity or challenge?’ – Bram Verstockt, clinician-scientist at the Gastroenterology-Hepatology Department at the University Hospitals Leuven, Belgium
17:50 – 18:10: ‘Designing Adaptive Clinical Trials for Combination Therapies in Type 1 Diabetes’ – Adrian Mander, Director of Statistics at the Centre for Trials Research in Cardiff University, UK.
18:10 – 18:25: Q&A
The second block of presentations: Translational challenges. Moderated by Antonio Julià, Head of Rheumatology Research Group in Vall d’Hebron Hospital Campus, Barcelona, Spain.
18:30 – 18:50: ‘Combining high-throughput perturbation experiments and mathematical modeling to identify efficacious combinations’ – Julio Saez–Rodriguez, Head of Systems Biomedicine Group, Heidelberg University, Germany.
18:50 – 19:10: ‘Leveraging multi-modal single-cell atlases to predict perturbations’ – Mohammad Lotfollahi, Institute of Computational Biology, Helmholtz Zentrum München, Germany.
19:10 – 19:30: ‘Network-based prediction of drug combinations’ – István Kovács, Head of Kovacs Labs: Complex Systems, Northwestern University, Evanston, USA.
19:30 – 19:45: Q&A
19:45-19:50: Closing by Sara Marsal, coordinator of the DOCTIS project and Head of Rheumatology Department in Vall d’Hebron Hospital Campus, Barcelona
News
Opinion
THIRD COUNTRIES
Paola Votta
EU Project Manager
Publication
LIFE
We present you the WHITE PAPER of the LIFE Programme, particularly valuable if you are thinking of submitting your proposal to the 2020 call.
To maximise the success and impact of a project, we manage the communication and dissemination activities, but we also define a social innovation strategy and tools to measure its impact.
We collaborate with public administrations to promote innovation and assist companies in integrating innovation into their overall strategy.
We are experts in European funding programmes, which provide the opportunity to finance the development and market access of your company's innovative projects.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.